Welcome to our dedicated page for Ensysce Biosciences news (Ticker: enscw), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
About Ensysce Biosciences Inc.
Ensysce Biosciences Inc. (NASDAQ: ENSCW) is a clinical-stage pharmaceutical company dedicated to addressing the critical challenges of severe pain management while reducing the risks associated with opioid abuse and overdose. Leveraging its proprietary Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the company is pioneering innovative, tamper-proof prescription drug solutions designed to enhance safety and efficacy.
Core Technologies and Value Proposition
Ensysce's TAAP™ technology chemically modifies opioids, making them inactive until metabolized by trypsin, a natural enzyme in the small intestine. This unique mechanism ensures controlled release and deters common abuse methods such as crushing or injecting. Complementing this is the MPAR® platform, which provides an additional layer of protection by shutting down opioid release when excessive doses are ingested, effectively preventing overdose. Together, these platforms represent a significant advancement in opioid safety, addressing both intentional and accidental misuse.
Product Pipeline and Clinical Development
Ensysce's lead drug candidates, including PF614 and PF614-MPAR, are designed to treat severe pain with reduced abuse potential. PF614 is an extended-release oxycodone prodrug, while PF614-MPAR combines TAAP™ technology with overdose protection. Both candidates have received FDA designations such as Breakthrough Therapy and Fast Track, underscoring their potential to transform pain management. The company is also exploring applications of its TAAP™ platform in treating opioid use disorder (OUD) and other therapeutic areas.
Industry Context and Market Position
Operating within the pharmaceutical industry, Ensysce addresses the growing demand for safer opioid alternatives amid the ongoing opioid crisis. Its innovative technologies align with regulatory priorities to combat opioid misuse and improve patient safety. The company benefits from a robust intellectual property portfolio and substantial federal grant funding, which support its R&D efforts and clinical programs. Ensysce's strategic collaborations with manufacturing and research partners further position it for success in a competitive landscape.
Challenges and Competitive Differentiation
While navigating the complexities of clinical trials and regulatory approvals, Ensysce faces competition from other pharmaceutical companies developing abuse-deterrent formulations. However, its dual-layered approach to abuse and overdose protection sets it apart, offering a comprehensive solution that addresses multiple facets of opioid safety. The company's focus on innovation, combined with FDA recognition and federal support, enhances its credibility and market potential.
Commitment to Safer Prescription Drugs
Ensysce Biosciences is committed to providing safer options for patients suffering from severe pain. By integrating advanced abuse-deterrent and overdose-protection technologies, the company aims to reduce the societal and individual harms associated with opioid medications. Its groundbreaking work represents a critical step toward addressing the dual challenges of effective pain management and opioid safety.
Ensysce Biosciences (NASDAQ:ENSC) has received a positive determination from Nasdaq regarding its listing status. The company has been granted an extension until November 14, 2024, to demonstrate compliance with the equity requirement by filing its Form 10-Q. Additionally, Nasdaq extended the deadline to December 19, 2024, for meeting the Minimum Bid Price requirement and other applicable conditions to maintain its listing on The Nasdaq Capital Market.
Ensysce Biosciences (NASDAQ:ENSC) announced its leadership team's participation in the 18th Annual Pain Therapeutics Summit on October 28-29, 2024, in Boston. Dr. Lynn Kirkpatrick, CEO, will present "When All You Have is a Hammer ... A New Approach to Soften the Blow" on October 28th at 1:00 PM ET. She will discuss Ensysce's TAAP™ and MPAR® opioid classes, including PF614 and PF614-MPAR, which aim to provide effective pain relief with reduced abuse potential and overdose protection.
Dr. William Schmidt, CMO, will serve as Chairperson for the second consecutive year, providing opening remarks on both days. The summit brings together leaders in advanced medicine, science, academia, and government to discuss the latest advances in novel pain therapies development.
Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing opioid abuse potential, provided a shareholder update. Key points include:
1. The company believes it's in compliance with Nasdaq requirements and awaits a hearing to discuss maintaining compliance.
2. Ensysce raised $5 million in gross proceeds and received a $14 million NIH grant.
3. The PF614-301 Phase 3 Protocol for a pivotal study was submitted to the FDA, with results expected in late 2025.
4. PF614-MPAR studies are progressing with non-dilutive funding.
5. The company aims to submit a New Drug Application for PF614 by 2026, with potential commercialization by year-end.
6. Ensysce is in discussions with potential partners to expand commercial success of PF614 and PF614-MPAR.
Ensysce Biosciences (NASDAQ:ENSC) has announced its participation in two upcoming meetings in October 2024. At the Society for Neuroscience meeting on October 5, new data will be presented on their Opioid Use Disorder (OUD) program, showcasing a study on methadone's effects in a modified rat model of physical dependence. This research, conducted with Sygnature Discovery, aims to develop novel methadone analogues with reduced cardiovascular side effects and abuse potential using Ensysce's Trypsin Activated Abuse Protection (TAAP) technology.
On October 16, Ensysce's CEO, Dr. Lynn Kirkpatrick, will present at the Formulation & Delivery US 2024 meeting, discussing their TAAP and MPAR platforms and highlighting their lead products, PF614 and PF614-MPAR. These products have received Fast Track and Breakthrough Therapy designations from the FDA, demonstrating their unique approach to delivering effective drugs more safely and efficiently.
Ensysce Biosciences (NASDAQ:ENSC) has released two video segments from its symposium at the International Association for the Study of Pain (IASP) 2024 World Congress in Amsterdam. The symposium focused on opioid use worldwide and Ensysce's innovative opioid drug products for severe pain relief. Dr. William Schmidt, CMO, explained the government support received from NIH and FDA, and highlighted how PF614, Ensysce's lead agent, aligns with ideal pain product characteristics. CEO Dr. Lynn Kirkpatrick emphasized the company's novel approach using TAAP and MPAR platforms to develop opioids with reduced abuse and overdose potential. Ensysce plans to begin a Phase 3 pivotal trial soon and explore PF614's use in cancer treatment, aiming to provide prescribers with new options for effective patient care.
Ensysce Biosciences (NASDAQ:ENSC) has received a $14 million multi-year grant from the NIH and National Institute on Drug Abuse (NIDA) for the continued development of PF614-MPAR, an abuse-deterrent opioid with overdose protection. This follows the FDA's Breakthrough Therapy designation for PF614-MPAR in January 2024. The funding will support the completion of the Phase 1b clinical trial, PF614-MPAR-102, over approximately three years.
PF614-MPAR is designed to provide optimal pain relief at prescribed doses while limiting accidental or intentional overdose. This grant brings the total federal funding awarded to Ensysce to $40 million, supporting their mission to develop innovative solutions for severe pain relief with reduced potential for opioid abuse and overdose.
Ensysce Biosciences (NASDAQ:ENSC) provides a mid-year 2024 update on its clinical-stage pharmaceutical developments for severe pain relief with reduced opioid abuse and overdose potential. Key highlights include:
1. PF614: Completed End of Phase 2 FDA meeting, published bioequivalence study results, and established manufacturing partnerships.
2. PF614-MPAR: Received FDA Breakthrough Therapy designation, applied for $15 million NIH/NIDA grant, and advanced to second clinical trial.
3. Opioid Use Disorder (OUD) program: Selected lead drug candidate PF9001, a TAAP methadone analogue with potentially lower cardiovascular side effects.
The company is finalizing the PF614 Phase 3 protocol and anticipates initiating enrollment later in 2024. Ensysce continues to seek non-dilutive federal funding to support its innovative pain relief solutions.
Ensysce Biosciences (NASDAQ:ENSC) announced it will host a symposium at the IASP 2024 World Congress on Pain on August 8, 2024, in Amsterdam. The symposium titled 'Severe Pain: A New Chapter for Safer Analgesics' will feature Dr. Lars Arendt-Nielsen and Dr. William Schmidt, who will discuss the landscape of severe pain treatment, trends in treatment, and the safety and effectiveness of Ensysce's PF614 and PF614-MPAR based on clinical data. CEO Dr. Lynn Kirkpatrick emphasized the importance of the event for presenting their technology platforms, TAAP and MPAR, which aim to reduce prescription drug abuse and overdose.
Ensysce Biosciences (NASDAQ:ENSC), a clinical-stage pharmaceutical company, announced a partnership with manufacturing expert Purisys to scale the production of its lead opioid use disorder (OUD) drug candidate, PF9001. Developed using Ensysce's TAAP technology, PF9001 aims to reduce the cardiovascular side effects commonly associated with methadone. This collaboration aims to expedite the drug's progression to IND studies. Ensysce is also advancing its pain treatment candidate, PF614, towards Phase 3 trials. CEO Dr. Lynn Kirkpatrick highlighted Purisys' expertise in controlled substance chemistry and its role in improving the manufacturing processes for PF614.
Ensysce Biosciences (NASDAQ: ENSC) has achieved a critical milestone in its opioid use disorder (OUD) program. The company has selected PF9001, a lead drug candidate designed to reduce abuse potential and improve safety, particularly with lower cardiovascular risks compared to traditional treatments. The candidate will proceed to Investigational New Drug (IND) enabling studies, backed by a $15 million NIH and NIDA HEAL award. CEO Dr. Lynn Kirkpatrick highlighted the adaptability of Ensysce's TAAP technology in producing controlled-activation drug candidates. Human clinical studies are expected to begin within 12 to 18 months.
FAQ
What is the current stock price of Ensysce Biosciences (enscw)?
What does Ensysce Biosciences Inc. specialize in?
What are TAAP™ and MPAR® technologies?
What are Ensysce's lead drug candidates?
How does Ensysce differentiate itself from competitors?
What challenges does Ensysce face?
How is Ensysce addressing the opioid crisis?
What is the significance of FDA designations for Ensysce?
What funding supports Ensysce's development efforts?
What is the market potential for Ensysce's products?
What partnerships does Ensysce have in place?
